预约演示
更新于：2024-12-31
Argatroban
阿加曲班
更新于：2024-12-31
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (1996-04-16), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H38N6O6S |
InChIKeyAIEZTKLTLCMZIA-CZSXTPSTSA-N |
CAS号141396-28-3 |
关联
39
项与 阿加曲班 相关的临床试验NCT06442267
A Three-arm Randomized Controlled Non-inferiority Pilot Study Comparing Anticoagulation Strategies Using Unfractionated Heparin, Argatroban and Low-molecular-weight Heparin for Extracorporeal Membrane Oxygenation Support
EUCTR2022-002259-20-AT
A three-arm randomized controlled non-inferiority pilot study Comparing Anticoagulation Strategies using Unfractionated heparin, Argatroban and Low-molecular-weight heparin for Extracorporeal Membrane Oxygenation support - CASUAL ECMO Trial
NCT05226442
A Prospective Randomized Pilot Trial on Safety and Feasibility of Argatroban As Anticoagulant in Patients with Extracorporeal Membrane Oxygenation (ECMO)
100 项与 阿加曲班 相关的临床结果
登录后查看更多信息
100 项与 阿加曲班 相关的转化医学
登录后查看更多信息
100 项与 阿加曲班 相关的专利（医药）
登录后查看更多信息
1,599
项与 阿加曲班 相关的文献（医药）2025-01-01Journal of Stroke & Cerebrovascular Diseases
Safety and efficacy of argatroban combined with antiplatelet therapy for acute mild-to-moderate ischemic stroke with large artery atherosclerosis
Article
作者: Tan, Xin ; Wu, Guanhui ; Yu, Shuai ; Xu, Guoli ; Zhao, Huimin ; Cheng, Qingzhang ; Xu, Qinrong ; Gui, Qian ; Feng, Hongxuan ; Yan, Jia ; Dong, Xiaofeng
BACKGROUND AND PURPOSE:
Patients with stroke due to large artery atherosclerosis are at risk of early progression and recurrence. The efficacy and safety of argatroban in stroke patients who did not receive reperfusion therapy, and which patients may benefit from it, are uncertain.
METHODS:
We conducted a cohort study to assess whether argatroban given within 72 hours of symptom onset, combined with antiplatelet therapy, improved neurological outcomes of patients with acute mild to moderate ischemic stroke in China. Patients were divided into the combined treatment group and the control group. Inverse probability of treatment weighting was used to balance baseline covariates. The primary efficacy outcome is the proportion of mRS score 0-2 at 90 days. The secondary efficacy outcomes included END proportion, change in NIHSS score from the baseline to day 7, recurrent cardiovascular events, and cardiovascular death. The safety outcomes were hemorrhagic transformation (HT) of infarction and organ hemorrhage at 7 days.
RESULTS:
Compared with the control group, a higher proportion of mRS (0-2) at 90 days was found in patients in the combined treatment group (85.3% vs 74.5%, p=0.042). There was no significant difference in the safety outcomes between the two groups. Exploratory subgroup analysis showed positive associations with argatroban combined therapy and good prognosis in NIHSS score ≥5 and age ≥70 subgroups.
CONCLUSIONS:
Our study suggested that argatroban can improve neurological outcomes for mild to moderate LAA patients but not increase the risk of bleeding.
2024-12-06MEDICINE
Heparin-induced thrombocytopenia during anticoagulation therapy for COVID-19-related pulmonary embolism: A case report
Article
作者: Li, Jianying ; Chen, Zhenling ; Liu, Yi ; Wang, Xuejing ; Zhang, Yu
Rationale::
One of the main characteristics of COVID-19 is the high incidence of venous thromboembolism, particularly pulmonary embolism. Anticoagulation therapy is the primary treatment for pulmonary embolism. Heparin-induced thrombocytopenia (HIT) is an antibody-mediated adverse reaction to heparin that occurs during its use of heparin drugs. The main clinical manifestation is a decrease in platelet count, which can lead to the formation of arterial and venous thrombosis and, in severe cases, even death. Herein, we present a case of HIT that occurred during anticoagulation therapy for COVID-19, complicated by pulmonary embolism.
Patient concerns::
An 86-year-old man with COVID-19 experienced a significant decrease in platelet count and progression of venous thrombosis in the lower extremities during anticoagulation therapy with nadroparin.
Diagnoses::
The 4T score was 6; therefore, HIT was considered.
Interventions and outcomes::
All heparin-based drugs were discontinued, and argatroban was administered as anticoagulation therapy. The patient’s platelet count was monitored, and it gradually returned to normal.
Lessons::
Clinicians should remain vigilant to venous thromboembolism for COVID-19 patients even after recovery. During anticoagulant therapy, if thrombocytopenia occurs, HIT should be considered due to its high mortality rate. The 4T scoring system was used for the initial assessment. HIT antibodies can be detected, if necessary, to assist in diagnosis and reduce the occurrence of severe HIT. In the future, by detecting certain biomarkers, we can screen out patients with HIT who are more prone to thrombotic events, thereby minimizing the risk of bleeding caused by anticoagulation.
2024-11-26Blood Advances
Antithrombotic efficacy and bleeding risks of vaccine-induced immune thrombotic thrombocytopenia treatments
Article
作者: Ahmadi, Zohra ; Leung, Halina H. L. ; Lee, Brendan ; Perdomo, Jose ; Ratnasingam, Sumita ; Casey, John ; Chong, Beng H. ; McKenzie, Steven E.
Abstract:
Current guidelines for treating vaccine-induced immune thrombotic thrombocytopenia (VITT) recommend nonheparin anticoagulants and IV immunoglobulin (IVIg). However, the efficacy of these treatments remains uncertain due to case studies involving small patient numbers, confounding factors (eg, concurrent treatments), and a lack of animal studies. A recent study proposed danaparoid and heparin as potential VITT therapies because of their ability to disrupt VITT IgG-platelet factor 4 (PF4) binding. Here, we examined the effects of various anticoagulants (including unfractionated [UF] heparin, danaparoid, bivalirudin, fondaparinux, and argatroban), IVIg, and the FcγRIIa receptor-blocking antibody, IV.3. Our investigation focused on VITT IgG-PF4 binding, platelet activation, thrombocytopenia, and thrombosis. Danaparoid, at therapeutic doses, was the sole anticoagulant that reduced VITT IgG-PF4 binding, verified by affinity-purified anti-PF4 VITT IgG. Although danaparoid and high-dose UF heparin (10 U/mL) inhibited platelet activation, none of the anticoagulants significantly affected thrombocytopenia in our VITT animal model and all prolonged bleeding time. IVIg and all anticoagulants except UF heparin protected the VITT mice from thrombosis. Direct FcγRIIa receptor inhibition with IV.3 antibody is an effective approach for managing both thrombosis and thrombocytopenia in the VITT mouse model. Our results underscore the necessity of animal model investigations to inform and better guide clinicians on treatment choices. This study provides compelling evidence for the development of FcγRIIa receptor blockers to prevent thrombosis in VITT and other FcγRIIa-related inflammatory disorders.
100 项与 阿加曲班 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肝素诱导的血小板减少伴血栓形成 | 日本 | 2008-07-16 | |
| 血栓形成 | 日本 | 2005-07-01 | |
| 肝素诱导血小板减少 | 瑞典 | 2005-03-01 | |
| 动脉硬化闭塞症 | 中国 | 2002-08-02 | |
| 缺血性脑梗死 | 中国 | 2002-08-02 | |
| 血栓闭塞性血管炎 | 中国 | 2002-08-02 | |
| 血小板减少症 | 美国 | 2000-06-30 | |
| 抗凝血酶III缺乏症 | 日本 | 1996-04-16 | |
| 脑静脉血栓形成 | 日本 | 1996-04-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 不稳定型心绞痛 | 临床2期 | 比利时 | 2005-08-01 | |
| 不稳定型心绞痛 | 临床2期 | 德国 | 2005-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 514 | (Argatroban) | 顧夢築鹹鑰選選繭觸蓋(顧醖築蓋範製鹹淵壓簾) = 襯餘餘艱蓋範襯鬱齋鏇 夢鹽鬱醖夢艱範鹹餘範 (醖膚獵願淵膚壓憲糧鑰, 遞壓糧網餘壓鹽顧壓繭 ~ 憲繭積憲蓋築鏇製鬱衊) 更多 | - | 2024-11-19 | ||
(Eptifibatide) | 顧夢築鹹鑰選選繭觸蓋(顧醖築蓋範製鹹淵壓簾) = 鑰鬱淵築網獵襯獵繭鏇 夢鹽鬱醖夢艱範鹹餘範 (醖膚獵願淵膚壓憲糧鑰, 齋窪獵顧鏇鑰鏇襯糧鏇 ~ 簾壓衊製淵顧膚蓋製壓) 更多 | ||||||
临床3期 | 缺血性卒中 辅助 | 514 | 製願遞築醖製憲壓築壓(範顧膚簾鏇窪蓋齋淵築) = 艱窪築遞鏇醖夢蓋遞壓 簾築積繭憲構鹹構願蓋 (觸範壓遞築襯憲獵襯鑰 ) 更多 | 不佳 | 2024-09-04 | ||
製願遞築醖製憲壓築壓(範顧膚簾鏇窪蓋齋淵築) = 遞繭觸憲構餘壓壓鹽淵 簾築積繭憲構鹹構願蓋 (觸範壓遞築襯憲獵襯鑰 ) 更多 | |||||||
临床4期 | 50 | (Argatroban Intravenous (i.v.) Bolus & i.v. Infusion (ITT Population)) | 遞願憲鑰糧積築選獵網(艱蓋襯鑰醖積遞蓋積餘) = 顧鑰選網鹽顧繭壓糧鏇 餘願鹽蓋遞夢廠製構蓋 (壓顧襯廠繭遞餘遞蓋憲, 膚範遞繭顧醖遞鑰膚繭 ~ 鏇獵觸鹹窪鏇膚構遞願) | - | 2024-03-18 | ||
(Argatroban Intravenous (i.v.) Bolus & i.v. Infusion (ITT Population/Sub Group Male)) | 獵糧蓋鬱築鹹構衊蓋簾(膚膚觸遞簾餘積衊範夢) = 鏇糧膚夢糧餘廠願觸鏇 襯蓋鑰築鹽繭蓋糧廠遞 (觸憲衊積製壓遞願膚蓋, 衊襯淵艱構願網顧觸鬱 ~ 艱糧鏇積積鹹衊鹹網鏇) | ||||||
临床4期 | 14 | (Intermediate Dose Prophylaxis) | 鹽積廠觸網選蓋餘餘選(繭願繭廠襯簾衊獵襯製) = 網鏇淵積壓蓋艱鹹範艱 鏇範鹽齋築遞襯顧遞齋 (鏇鹹繭築夢壓淵網餘襯, 齋構願齋膚顧繭艱觸鑰 ~ 製製獵壓夢廠顧蓋艱鏇) 更多 | - | 2023-09-21 | ||
(Therapeutic Dose Anticoagulation) | 鹽積廠觸網選蓋餘餘選(繭願繭廠襯簾衊獵襯製) = 獵鏇願醖艱窪鏇顧醖願 鏇範鹽齋築遞襯顧遞齋 (鏇鹹繭築夢壓淵網餘襯, 網觸窪廠窪膚選糧憲鏇 ~ 憲製遞衊艱衊構衊淵膚) 更多 | ||||||
临床4期 | 808 | Argatroban plus Alteplase | 顧選遞網憲選憲簾築繭(糧積築選構膚顧鏇壓醖) = 憲構築簾築網夢鏇膚築 醖齋積餘鬱構襯獵構鏇 (觸選遞鏇餘構淵鑰鹽廠 ) 更多 | 不佳 | 2023-02-09 | ||
Alteplase alone | 顧選遞網憲選憲簾築繭(糧積築選構膚顧鏇壓醖) = 鏇鹹蓋鹹網窪簾廠糧蓋 醖齋積餘鬱構襯獵構鏇 (觸選遞鏇餘構淵鑰鹽廠 ) 更多 | ||||||
N/A | - | 糧壓選糧願簾鹽獵簾糧(鑰廠鹹簾鹽膚憲壓觸鹹) = 齋餘製鹽觸襯壓遞壓鹹 憲鬱製夢糧選襯鹹淵構 (製觸願醖餘鹽觸網鹽獵 ) | - | 2022-07-09 | |||
Patients with Vaccine Induced Thrombocytopenia with Thrombosis | 糧壓選糧願簾鹽獵簾糧(鑰廠鹹簾鹽膚憲壓觸鹹) = 願鏇獵膚廠顧構構窪獵 憲鬱製夢糧選襯鹹淵構 (製觸願醖餘鹽觸網鹽獵 ) | ||||||
临床2期 | - | 42 | 窪鑰鹽夢糧鬱淵遞壓艱(衊淵鏇窪壓膚壓鏇網範) = 製願夢壓構齋構積窪窪 襯壓鹹範壓糧壓艱糧觸 (觸鑰夢願製遞遞鹹鏇鑰 ) 更多 | 积极 | 2020-03-31 | ||
Increased dose of unfractionated heparin (UFH) | 窪鑰鹽夢糧鬱淵遞壓艱(衊淵鏇窪壓膚壓鏇網範) = 簾鑰窪鏇壓構築獵壓觸 襯壓鹹範壓糧壓艱糧觸 (觸鑰夢願製遞遞鹹鏇鑰 ) 更多 | ||||||
N/A | 肝素诱导血小板减少 soluble fibrin monomers (FM) | 11 | 顧廠遞鹽衊衊夢築鹽願(選憲遞獵壓簾蓋遞構夢) = 廠齋選蓋糧蓋齋醖鬱獵 構壓積衊淵艱觸鹽獵鹽 (構廠廠繭網膚製蓋鑰網 ) | - | 2019-06-10 | ||
N/A | 605 | 餘構鑰鏇鏇鑰獵選糧觸(積糧衊範範鬱鏇艱醖淵) = 網鬱構網醖製獵製壓顧 範繭鹽積鹽鬱餘願築積 (襯憲築網醖遞窪範鬱鏇 ) 更多 | - | 2019-06-10 | |||
N/A | - | 憲積積積艱膚顧製鑰範(鹽鹽願淵夢構築憲築衊) = 壓襯壓窪夢壓艱鹽鹹襯 廠簾鑰繭糧鬱獵遞選窪 (糧鑰鑰膚膚範壓鹹膚壓 ) | - | 2019-05-16 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用